期刊文献+

窦性心动过缓患者阿托品试验前后QTd变化 被引量:4

Changes of QT Dispersion before and after Atropin Test in Patients with Sinus Bradycardia
下载PDF
导出
摘要 目的 探讨迷走神经对QT间期离散度的影响。方法 观察 12 2例窦性心动过缓者阿托品试验前后QTd和QTcd的变化。结果 注射阿托品后 3分钟内单纯窦性心动过缓组QTd和QTcd虽然缩短 ( 19.72± 12 .82ms对 2 5 .99± 10 .33ms ;17.5 4± 10 .18ms对 2 2 .84± 11.34ms) ,但无统计学差异 (P >0 .0 5 ) ;急性胆囊炎组明显缩短 ( 16 .6 6± 10 .0 0ms对2 8.89± 13.33ms ,P <0 .0 5 ;15 .0 9± 11.18ms对 2 4.35± 8.92ms ,P <0 .0 1) ;胆囊炎并缺血性心脏病组则显著延长 ( 6 6 .9± 14 .18ms对 2 9.78± 12 .5 4ms ;6 4.2 1± 15 .0 6ms对 2 6 .10± 10 .10ms ,P <0 .0 5 )。结论 提示迷走神经兴奋对缺血性心肌具有保护作用。 Objective To investigate the effect of vagus nerve on QT dispersion in the patients with sinus bradycardia.Method The changes of QT dispersion (QTd) and QTc dispersion(QTcd) before and after atropin test in 122 cases were observed,which were divided into group Ⅰ(single sinus bradycardia group),group Ⅱ(acute cholecystis group) and group Ⅲ(cholecystis complicated with ischemic heart disease group).Results (1)There was no significant difference before the test among 3 groups( P >0.05).(2)3 minutes after the test,QTd and QTcd in group Ⅰ were shorter(19.72±12.8ms vs 25.99±10.33ms;17.54±10.18ms vs 22.84±11.34ms),but there was no significant difference(all P >0.05);(3)QTd and QTcd in group Ⅱ were significantly shorter(16.66±10.00ms vs 28.89±11.33ms, P <0.05;15.09±11.18ms vs 24.35±8.92ms, P <0.01);(4)QTd and QTcd after the test in group Ⅲ were longer than those of pretest(66.01±14.18ms vs 29.78±12.54ms;64.21±15.06ms vs 26.10±10.10ms, P <0.05).Conclusions The role of enhanced vagal activity on ischemic mycardium may provide it with protection.
出处 《现代诊断与治疗》 CAS 2001年第6期333-334,共2页 Modern Diagnosis and Treatment
关键词 QT离散度 阿托品试验 窦性心动过缓 迷走神经张力 QT dispersion Atropin test Sinus bradycardia Vagus activity
  • 相关文献

参考文献1

  • 1王小栋 徐有恒.植物神经系统生理学----基础与临床[M].北京:科学技术出版社,1994.159-160.

同被引文献15

  • 1王钢.服用倍他乐克致窦性心动过缓伴持续14秒以上窦性停搏一例报告[J].第二军医大学学报,2006,27(2):214-214. 被引量:6
  • 2吴彩贤.病态窦房结综合征的治疗进展[J].临床荟萃,1996,11(2):49-50. 被引量:7
  • 3郝国栋 李莉.137例窦性心动过缓老年人动态心电图分析[J].当代医学,2007,(114):39-40.
  • 4Reves JG.Educational considerations for the clinical introduction and use of remifentanil[J].Anesth Analg,1999,89(4 Suppl):S4-6.
  • 5Glass PS,Gan TJ,Howell S.A review of the Pharmacokinetics and Pharmacodynamics of remifentanil[J].Anesth Analg,1999,89(4 Suppl):S7-14.
  • 6Egan TD.Remifentanil pharmacokinetics and pharmacodynamics.A preliminary appraisal[J].Clinical pharmacokinetics,1995,29(2):80-82.
  • 7郭继鸿.心电图学[M].北京:人民卫生出版社,2005:1030.
  • 8张智勇.益气调心汤治疗窦性心动过缓40例[J].河南医学,2010,10(2):993-994.
  • 9Svarstad B L, Chewning B A, SLEATH B L, et al. The Brief Medication Questionnaire:a tool for screening patient ad- herence and barriers to adherence. Patient Educ Couns, 1999,37 (2) : 113 - 124.
  • 10季建国,侯小锋,张荣,殷海萍,夏耘,涂静,宋志慧,张志华,邹建刚,曹克将.窦性心动过缓人群心脏变时性功能的评价[J].南京医科大学学报(自然科学版),2008,28(9):1116-1119. 被引量:5

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部